Aim: Studies have demonstrated neuropsychological deficits across a variety of cognitive domains in depression. These deficits are observable both in major depressive disorder (MDD) and in bipolar disorder (BD) and are present in each phase of the illness, including euthymia. Adverse childhood experiences (ACE) have been associated with an increased risk of developing psychiatric disorders and cognitive deficits. The aim of this study was to assess neuropsychological performances in a sample of MDD and BD patients during a depressive episode compared to healthy controls (HC) and, to investigate if ACE affect the cognitive profiles in the three groups.
M
OOD DISORDERS, INCLUDING both depressive and bipolar disorders, have one of the highest lifetime prevalences among psychiatric disorders. Bipolar disorder (BD) is a chronic and severe psychiatric illness characterized by an early onset 1 and a cyclic alternation of manic and depressive episodes, whereas major depressive disorder (MDD) patients experience long periods of decreased mood, self-esteem, energy, and interests. Beside clinical symptoms, both disorders are characterized by impaired cognitive performances involving several cognitive domains: attention, working memory, verbal fluency, attention/speed of information processing, and executive functions. [2] [3] [4] [5] [6] [7] Moreover, even if cognitive deficits are more severe during active phases (depressive and/or manic episodes), they are still also present during euthymia, probably representing a core feature of these pathologies. 8, 9 The cognitive impairment also impacts the daily Stress is an environmental variable that exerts a detrimental effect on mental and physical well-being, representing a risk factor for several psychiatric disorders. 10 The neurobiological and psychological effects of child neglect, abuse, or trauma persist during adulthood, representing fundamental factors influencing people's health status. Adverse childhood experiences (ACE) influence several aspects of psychiatric disorders outcome: (i) they predict antidepressant response; 11 (ii) they influence brain structure and function in depressive, anxious, and psychotic disorders; [12] [13] [14] [15] [16] [17] (iii) they influence the levels of peripheral proinflammatory cytokines; 18 (iv) they worsen mood-congruent cognitive distortions in depression; 19 (v) they increase the risk of suicide; 20, 21 and (vi) they increase the overall severity of the disorders. 22 Exposure to ACE seems to influence cognitive performances both in childhood and adulthood. Children experiencing high levels of ACE in their family environment show lower IQ scores and impaired cognitive function in core domains for abstract reasoning and academic functioning. 23 This effect seems to be unrelated to genetic influences, 24 thus underlying the detrimental effect of ACE on neurobiological and mental development.
Following this line of reasoning, the aim of our study was to investigate whether exposure to ACE can moderate the effect of diagnosis on cognitive performances in BD patients, MDD patients, and healthy controls (HC).
METHODS

Sample
The sample included 57 biologically unrelated inpatients with a diagnosis of MDD (DSM-IV criteria, Structured Clinical Interview for DSM-IV Disorders [SCID]) without psychotic features, 76 biologically unrelated inpatients with a diagnosis of BD I (DSM-IV criteria, SCID-I interview) without psychotic features, and 57 HC. Exclusion criteria were: additional diagnoses on axis I, mental retardation on axis II, pregnancy, major medical and neurological disorders, and history of drug or alcohol abuse or dependency. Physical examination, laboratory tests, and electrocardiograms were performed at admission. No patient had received electroconvulsive therapy within 6 months prior to study enrolment. After complete description of the study to the participants, written informed consent was obtained. The study was approved by the local ethics committee.
Clinical assessment
Severity of depression was rated on the 21-item Hamilton Depression Rating Scale (HDRS).
Severity of ACE was rated on the Risky Families Questionnaire (RFQ) 25 after magnetic resonance imaging scanning. The RFQ has been adapted from an instrument originally developed to assess the relation of family stress to mental and physical health outcomes in adulthood. 26 The instrument is aimed at rating the degree of harsh parenting with overt family conflict and deficient nurturing experienced by the children in their familial environment. Previous research validated this questionnaire against clinical interviewers; the dual assessment (questionnaire and interview) demonstrated high agreement and reliability. 27 To caution against the non-linear relation among variables and against the differential distribution of ACE in respect to diagnosis, we used the median split. Each group of participants was divided into two subgroups, using median values as a discriminant between high and low scores of the RFQ. 30 Given these data, we decided to replace the Tower of London task with the WCST. WCST normative Italian adjusted scores 31 were used to evaluate the goodness-of-executive-functions performances. Among the output measures of the WCST, we used as an index of cognitive flexibility the perseverative errors score, which reflects the failures to change sorting strategy after negative feedback. All tests were administered by a trained psychologist. To exclude the potential effect of psychotropic medication load, reflecting the number and dosage of different medications, we used a strategy that has been developed for this measurement. 32, 33 For antidepressants and mood stabilizers, we categorized each medication into low-dose or high-dose groupings, a method validated in brainimaging studies. 34 We converted antipsychotics to chlorpromazine hydrochloride dose equivalents, coding them as 0 (no medication), 1 (equal to or below the chlorpromazine dose equivalent), or 2 (above the chlorpromazine dose equivalent) relative to the mean effective daily dose of chlorpromazine as defined previously. 35 Benzodiazepine dose was coded as 0, 1, or 2 relative to the midpoint of the recommended daily dose range for each medication recommended in the Physicians' Desk Reference. We generated a composite measure of medication load by summing all individual medication codes for each medication category for each individual participant.
Neuropsychological assessment
Data analysis
To address statistically significant group differences for sex distribution and age in patients and controls, age-and sex-stratified normative data 29 were used to compute subtest and global scores for each participant on the BACS. Moreover, to provide a standard metric for comparison across neurocognitive domains for each subtest, an equivalent score, ranging from 0 to 4, was obtained. Standardized domain scores were calculated for symbol coding (Selective Attention), digit sequencing (Working Memory), Verbal Memory, Token Motor Task (Psychomotor Coordination), and the WCST (Executive Functions).
Given the number of cognitive outcome measures, we began data analysis with an omnibus test comparing the BD and control groups on the global cognitive index of neurocognitive performance. In the presence of a significant group difference on the global neuropsychological measure, step-down domain-wise analyses were undertaken. Analyses of variance were performed to investigate the main effect of diagnosis on the global and singles cognitive measures and the post-hoc Fisher least significant difference (LSD) method for multiple comparisons was performed to investigate differences between groups. Then we investigated if the effect of diagnosis on cognitive performances could be moderated by ACE. A possible moderator role of ACE on the effect of diagnosis on cognitive performances was investigated within the context of the general linear model with cognitive scores adjusted for age, sex, and education as dependent variables, and diagnosis and ACE (high and low) as categorical predictors. Profile analyses in the whole sample and divided according to ACE (high-low) were conducted using a multivariate analysis of variance (MANCOVA), with groups as between factor and subtests as within factor, and with the group-by-subtest interaction as the main effect of interest. HDRS score was added in all analyses as nuisance covariate to correct for the severity of illness.
RESULTS
Clinical and demographic characteristics of the sample are summarized in Table 1 . Significant differences among the three groups were observed in terms of age and education; Fisher's post-hoc LSD showed that HC were younger and had a higher education than both BD (P < 0.001) and MDD (P < 0.001) patients. No difference was observed between BD and MDD patients. Significant differences among the three groups were observed for the RFQ score, with MDD patients reporting more ACE compared to both HC (LSD P < 0.001) and BD patients (LSD P = 0.04); no difference was observed between BD patients and HC. Neuropsychological performances (raw scores) of patients and controls are summarized in Table 1 and are shown in Figure 1 .
To establish baseline deficits in subjects with BD, group differences on the mean equivalent score were tested. Results showed a significant effect of diagnosis (F = 74.52, P < 0.001). Fisher's LSD post-hoc indicated that both BD (P < 0.001) and MDD (P < 0.001) groups performed significantly worse than the HC group, and that BD patients performed worse than MDD subjects (P = 0.007). In addition to the effect of diagnosis, we also observed a significant effect of ACE on the global cognitive measure, with subjects who experienced higher levels of ACE reporting worse cognitive performances irrespective of diagnosis (F = 6.24, P = 0.014).
Given the observed significant global deficit, cognitive performances in each neuropsychological domain were investigated. Results indicated a significant effect of diagnosis in all six domains, with HC showing better performances compared to both patients groups: Verbal Memory (F = 21.74, P < 0.001; LSD HC vs BD, P < 0.001; LSD HC vs MDD, P < 0.001), Working Memory (Digit Sequencing: F = 11.08, P < 0.001; HC vs BD, P < 0.001; LSD HC vs MDD, P = 0.006), Psychomotor Coordination (Token Motor Task: F = 40.08, P < 0.001; HC vs BD, P < 0.001; LSD HC vs MDD, P < 0.001), Verbal Fluency (F = 14.18, P < 0.001; HC vs BD, P < 0.001; LSD HC vs MDD, P = 0.009), and Selective Attention (Symbol Coding: F = 54.75, P < 0.001; HC vs BD, P < 0.001; LSD HC vs MDD, P < 0.001). For executive functions, a significant effect of diagnosis was observed (WCST: F = 6.19, P = 0.003); post-hoc LSD test showed a significant difference only between HC and BD patients (P < 0.001), and no difference was observed between MDD patients and the other groups. MDD subjects showed better performances compared to BD patients in Verbal Fluency (LSD, P = 0.03). No significant difference between MDD and BD subjects was observed for the remaining variables.
When investigating whether ACE moderated the effect of diagnosis on cognitive performances, we observed an interaction between ACE and diagnosis on Speed of Information Processing (Symbol Coding; F = 5.71, P = 0.004). Patients with high ACE performed worse than the low ACE group, whereas the opposite pattern was observed for HC. No difference was observed between patients.
A MANCOVA testing for profile differences indicated a significant group-by-subtest interaction (F = 2.11, P = 0.025) in the high ACE group. Effects of diagnosis revealed only in the high ACE group, while no difference between diagnostic samples was observed in the low ACE group. When the comparison group was excluded, the group-by-subtest interaction for patient groups was not significant, indicating that their pattern of performance did not differ across cognitive domains. A cognitive profile of the three groups divided according to ACE is shown in Figure 2 .
No significant correlation was observed between medication load and neuropsychological variables. 
DISCUSSION
The nature and extent of the association between depression and cognitive impairment are not fully understood yet. Some studies have suggested that cognitive impairment in depression is limited 36, 37 and linked with the severity of illness. 38 Other studies have suggested that cognitive deficits may be a trait risk factor for depression 39 and that similar widespread deficits are present in MDD and BD. 40 In our study, considering the whole sample, patients obtained significantly lower domain scores across the entire battery compared to healthy subjects. The same neuropsychological profile of cognitive dysfunction was observed in previous studies using the BACS: one in a broad sample of psychotic BD and schizophrenic patients 41 and the other in a sample of BD patients before and after chronotherapeutic treatment. 42 However, when considering the effect of ACE, only a subgroup of patients effectively showed cognitive impairment. This is the first study to investigate a possible moderating role of ACE on cognitive performances. First, looking at single performances we observed a significant diagnosis × ACE interaction on Speed of Information Processing. Second, we observed a different cognitive profile according to the exposure to ACE. Whereas patients exposed to high ACE performed significantly worse than HC across almost all domains, in the low ACE sample, no significant group by subset interaction was observed. In light of these results, only MDD and BD patients who experienced higher ACE seemed to share the same cognitive deficits, albeit with different degrees of severity. These data are in agreement with previous studies showing that exposure to ACE has adverse effects on cognitive function, both in childhood and in adulthood. 43 Childhood trauma, as suggested by a study on pediatric bipolar patients, may lead to a developmental delay in some neurocognitive functioning, which has effects also persisting into adulthood. 44 Although evolutionary models of behavior suggest that childhood adversity could shape cognition in adaptive ways, 45 this could be true in healthy subjects but several mechanisms could prevent these adaptive changes from happening in psychiatric disorders.
Different mechanisms could explain the detrimental effect of ACE on cognitive functions. First, changes in the environment have been shown to produce changes in the epigenetic regulation of genes. As suggested by Kundakovic and Champagne 46 epigenetic mechanisms are at the forefront of how frequently early life experiences alter DNA expression over the lifetime of the organism. Animal studies have demonstrated that maternal care alters gene expression through DNA methylation. For example, social isolation stress significantly increases the expression of adenosine deaminase acting on RNA (ADAR1), an enzyme involved in RNA editing that has a close relation to cognitive function in the hippocampus and frontal cortex of mice with cognitive deficit. 47 In humans, elevated DNA methylation across a region spanning the transcription start site of the cytochrome P450 2E1 (CYP2E1) gene was associated with impaired cognition following institutional deprivation and childhood abuse. 48 Finally, post-mortem studies in patients with BD and MDD showed epigenetic regulation of the glucocorticoid receptor in peripheral blood leucocytes. 49 These data suggest that early stress may have a biological impact during early development, thus leading to long-lasting epigenetic changes, reflecting a possible biological mechanism underlying the cognitive effects of ACE.
Second, neuroinflammation (i.e. inflammation in the context of the nervous system) has been widely reported in patients with psychiatric disorders 50 and it is typically associated with microglial activation. A chronic activation of the immune system by microglia produces cytokines that render the brain vulnerable and unstable, thus leading to mood disturbances 51 and to behavioral and cognitive deficits. 52, 53 Neuroimmune activation has been associated with stress-induced cognitive deficits in mice 54 and the animal literature suggests that regions important for cognition may be particularly vulnerable to early life disruption by immune activation. In humans, cognitive impairment, including learning, memory, and attention disorders, is one of the most consistent consequences of early infections or trauma 43, 55 and neuroinflammatory biomarkers have been associated with cognitive impairment in BD. 56 Bilbo and colleagues suggest that an individual's risk or resilience to neuroinflammatory disorders and cognitive dysfunction may depend on their early life experience, which can change immune reactivity within the brain for the remainder of the lifespan. 57 Both epigenetic changes and neuroinflammation can impact on brain structure, leading to gray and white matter abnormalities. Accordingly, in previous studies we have observed that ACE can influence the integrity of white matter microstructure in BD and schizophrenia 13, 58 and that this same integrity is associated with neurocognitive performances in BD 59 and with levels of circulating cytokines. 60 Furthermore, we observed that ACE moderate the detrimental influence of a psychiatric diagnosis on gray matter volume both in BD and in schizophrenia.
These findings suggest that early stress may induce epigenetic changes or an inflammatory state that may interact with psychiatric disorders and their genetic characteristics, thus leading to partially overlapping phenotypes like those observed in BD, MDD, and schizophrenia.
Several non-pharmacological strategies have been developed to address cognitive functioning (such as cognitive remediation therapy) and other psychosocial approaches (such as supported employment services and social skill training, which have been demonstrated as potentially effective at improving social functioning). However, several intervening factors may impact the outcome of these treatment strategies. For example, besides affecting cognitive performances, ACE could impact on the plastic abilities of the brain, thus influencing the response to therapeutic intervention.
Limitations of this study include issues such as generalizability, possible undetected past comorbidities, and population stratification. The use of medications varied among patients and also between the MDD and BD groups. It was thus very difficult to control for the potentially negative effect of medication on cognitive performances, especially as the HC group was not taking any medication. The medications used may have either enhancing or detrimental effects on cognition, even with the same drug. For example, it is still unknown how to reconcile the adverse and neuroprotective effects of agents such as mood stabilizers on cognitive performances. Future studies should aim at differentiating medication from illness-induced cognitive dysfunction, which will require comprehensive assessment with an appreciation for the cognitive domains most affected by specific medication.
In conclusion, this study confirms that cognitive impairment is not specific to patients with schizophrenia but is also seen in both MDD and BD, albeit in different degrees of severity. Furthermore, the study highlights the importance of early stress when investigating cognitive functions in mood disorders. The accurate identification and quantification of neurocognitive impairment are important for research relating to neurobiological underpinnings, treatment, and functional outcome in patients with mood disorders. Early stress and cognitive impairment have widespread psychosocial and functional consequences, and future studies should investigate the adaptive and real-life implications of the effect of early stress on cognitive impairments. Moreover, studies are also needed to understand whether the efficacy of remediation strategies can be influenced by ACE and to further tailor these interventions for those exposed to ACE. Finally, prevention strategies should be developed in order to counteract the detrimental influence of early stress on cognitive functions.
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